
## U.S. NUCLEAR REGULATORY COMMISSION

## **MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.



NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION		PAGE 2 OF 3 PAGES
	License No.: 53-15737-01	Docket or Reference No.:	
MATERIALS LICENSE		030-09666	
SUPPLEMENTARY SHEET	Amendment No. 61		

## **CONDITIONS**

- 10. Licensed material shall be used or stored at the licensee's facilities located at 3-3420 Kuhio Highway, Lihue (island of Kauai), Hawaii, 96766.
- 11. The Radiation Safety Officer (RSO) for this license is Allen Johnson, M.D.
- 12. Licensed material shall only be used by, or under the supervision of:
  - A. Individuals permitted to work as authorized users, authorized nuclear pharmacists, and/or authorized medical physicists in accordance with 10 CFR 35.13 and 10 CFR 35.14.
  - B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User (M.D.,D.O.,etc.)	Material and Use
Martin R. Engel, M.D.	35.100; 35.200; Oral Administration of less than or equal to 1.22 gigabecquerels (33 millicuries) of sodium-iodide I-131, for which a written directive is required
Allen Johnson, M.D.	35.100; 35.200; 35.300
Mary Mackiernan, M.D.	35.100; 35.200
Michael May, M.D.	35.100; 35.200
Christopher D. Orlang, M.D.	35.100; 35.200; Oral administration of sodium iodide I-131
Andrew So, D.O.	35.200
Ramya Srinivasan, M.D.	35.100; 35.200; Oral administration of sodium iodide I-131

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMM	ISSION	PAGE 3 OF 3 PAGES		
MATERIALS LICENSE SUPPLEMENTARY SHEET	License No.: 53-15737-01	Docket or Reference No.: 030-09666			
	Amendment No. 61				
13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.  A. Application dated July 14, 2015 (ML15211A472)					
FOR THE U.S. NUCLEAR REGULATORY COMMISSION					
Date: <u>June 25, 2023</u>		atischa M. Hanson Region IV			